Natco Pharma's Q1 FY 2025-26 Quarterly Results

Result Summary

• Natco Pharma Ltd reported a 25.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 1.4%.
• Its expenses for the quarter were up by 29.4% QoQ and 34.9% YoY.
• The net profit increased 24.3% QoQ and decreased 28.2% YoY.
• The earnings per share (EPS) of Natco Pharma Ltd stood at 26.8 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Natco Pharma Ltd is a prominent pharmaceutical company primarily engaged in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients. The company is known for its focus on niche therapeutic areas and complex products. Natco Pharma has a significant presence in both domestic and international markets, including the United States, Europe, and other emerging markets. It has been involved in the production of generic drugs, particularly in the oncology segment, and has made considerable advancements in the development of new drug formulations. Any recent major developments for Natco Pharma are not specified in the provided data.

Revenue

In Q1FY26, Natco Pharma Ltd reported a total income of ₹1390.60 crores. This represents a quarter-over-quarter (QoQ) increase of 25.2% from Q4FY25, where the total income was ₹1110.30 crores. However, when compared year-over-year (YoY) to Q1FY25, which recorded a total income of ₹1410.70 crores, there is a slight decrease of 1.4%. The fluctuation in total income highlights the quarter's performance relative to both the previous quarter and the same period last year.

Profitability

For Q1FY26, Natco Pharma's profit before tax was reported at ₹571.90 crores, which marks a 19.7% increase QoQ from ₹477.60 crores in Q4FY25. Despite this quarterly improvement, there is a significant YoY decrease of 28.8% when compared to Q1FY25's profit before tax of ₹803.60 crores. The profit after tax for the current quarter stood at ₹480.30 crores, reflecting a 24.3% increase QoQ from ₹386.30 crores in Q4FY25, yet showing a 28.2% decline when compared YoY to ₹668.50 crores in Q1FY25. The tax expense for Q1FY26 was ₹91.60 crores, showing minimal change from the previous quarter but a 32.2% decrease YoY.

Operating Metrics

In Q1FY26, the company's total expenses amounted to ₹818.70 crores, which is a 29.4% increase QoQ from ₹632.70 crores in Q4FY25, and a 34.9% increase YoY from ₹607.10 crores in Q1FY25. This increase in expenses is notable both in the short term and compared to the same period last year. Earnings per share (EPS) for Q1FY26 were reported at ₹26.80, which is a 24.1% increase QoQ from ₹21.60 in Q4FY25, but a 28.2% decrease YoY from ₹37.30 in Q1FY25. The trends in expenses and EPS reflect the company's operating performance over the reported periods.